<DOC>
	<DOCNO>NCT00300053</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety intramyocardial injection adult stem cell patient refractory chronic myocardial ischemia .</brief_summary>
	<brief_title>ACT34-CMI -- Adult Autologous CD34+ Stem Cells</brief_title>
	<detailed_description>This double-blind , prospective , randomize , placebo-controlled trial determine tolerability , efficacy , safety dose range intramyocardial injection adult autologous CD34+ cell mobilize granulocyte colony stimulate factor reduction angina episodes patient refractory chronic myocardial ischemia .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>2180 year age CCS functional class III IV chronic refractory angina unsuitable conventional revascularization predominant congestive heart failure leave ventricular ejection fraction le 25 % screen myocardial infarction within 60 day treatment successful coronary revascularization within 6 month study enrollment history moderate severe aortic stenosis prosthetic aortic valve comorbidity associate life expectancy le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>angina</keyword>
</DOC>